Xgeva (denosumab), which has already been approved by the Food and Drug Administration (FDA) for the prevention fractures in men with advanced prostate cancer that has already migrated to the bone, has been rejected by the FDA to expand the use of the drug to delay the spread of tumors in men without metastases to [...]
The Prostate Cancer Research Program (PCRP) of the Department of Defense, Congressionally Directed Medical Research Programs (CDMRP) has received our fiscal year 2012 (FY12) funding to support research projects in the prevention, detection, diagnosis, and treatment of Prostate Cancer. This is a critical request and it is important that prostate cancer survivors participate in research [...]
Despite the fact that we have had good research for well over 15 years that show that early hormone therapy increases over all survival, some doctors still insist on delaying the start of hormone therapy. A UK randomized trial done in 1997 demonstrated a slight impact of immediate versus deferred hormone suppression in advanced prostate [...]
For those who might be interested in the April 23, 2012 edition of The New Yorker Magazine, Jerome Groopman has written an excellent article on the history and current state of Immunotherapy. The article is entitled "The T-Cell Army" and it is on page 24. Not only does the article review the history (going all [...]
Resveratrol (3,4’-trihydroxystilbene) is a natural product that can be found in significant concentrations food products like red wine, peanuts, walnuts etc. There have been some evidence that indicates that resveratrol has anti-tumorigenic activity, including in prostate cancer tumors. The precise mechanism associated with resveratrol-induced SIRT1 activation and cancer cell growth inhibition remains unclear, but we [...]